Role of non-coding sequence variants in cancer

Area of Science:

• Genomics
• Cancer Biology
• Molecular Oncology

Background:

• Cancer patients possess both inherited germline and acquired somatic genetic variants.
• While protein-coding variants are well-studied, non-coding variants represent the majority of both germline and somatic alterations in cancer genomes.
• The functional impact of non-coding variants on tumorigenesis is increasingly recognized.

Purpose of the Study:

• To review the current understanding of non-coding variants in cancer.
• To explore the diverse mutation types and mechanisms by which non-coding variants influence gene expression and promote cancer.
• To discuss computational and experimental approaches for interpreting non-coding variants.

Main Methods:

• Literature review of current research on non-coding variants in cancer.
• Analysis of mutation types, including single nucleotide variants and large genomic rearrangements.
• Examination of mechanisms affecting gene expression, such as disruption of transcription factor-binding sites and non-coding RNA functions.
• Case study analysis of specific somatic and germline variants.
• Discussion of large-scale interpretation methods using computational and experimental approaches.

Main Results:

• Non-coding variants encompass a wide spectrum of mutation types, from single nucleotide variants to large genomic rearrangements.
• These variants can promote tumorigenesis by altering gene expression through mechanisms like disrupting transcription factor binding or affecting non-coding RNA functionality.
• Specific examples of somatic and germline non-coding variants illustrate their role in cancer development.
• Computational and experimental methods are essential for large-scale interpretation of non-coding variants.

Conclusions:

• Non-coding variants are a major source of genetic alterations in cancer, significantly contributing to tumorigenesis.
• A comprehensive understanding of the diversity and functional impact of non-coding variants is critical for advancing cancer genomics.
• Interpreting non-coding variants through integrated computational and experimental strategies is key to unlocking their diagnostic and therapeutic potential.